These medicines include injectable formulations such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon BCise), as well as oral semaglutide (Rybelsus)
Aggio, R
Clinical translation requires human CSF pharmacokinetic assays to prove BBB bypass, a rigorous dose-escalation Phase I trial to establish a safe human NOAEL for chronic dosing, and an RCT utilizing precise neurocognitive testing (e.g., MoCA) to confirm that murine transcriptomic shifts yield functional neuroprotection in humans
The mechanism of action of siRNA enables longer-lasting effects and lower dosing frequencies than ASO-based therapies do
Drugs currently being tested that target AATs are shown in (Table 1)
Incretin-based therapies in type 2 diabetes mellitus